We experienced one case of SC fungemia in a premature female infant (29⁺³ weeks, 1.56 kg) with respiratory distress syndrome (RDS) after intake of Bioflor-250 Powder (Lyophilized Saccharomyces cerevisiae Hansen CBS 5926 282.5 mg, Gunil Pharmaceutical Co., Seoul, South Korea) under ampicillin and clarithromycin treatment. She presented with decreased activity, chest retraction and dyspnea. Initial complete blood count showed hemoglobin 15.9 g/dL, leukocyte count 10.7×10⁹/L (neutrophils, 23%, lymphocytes 71%) and platelet count 295 x10⁹/L. Blood culture showed non-specific findings. On the 35th hospital day, Bioflor-250 powder was administered orally, two times a day for 15 days. From the 45th hospital day, isolates from two serial blood cultures were identified as yeast in the blood agar plate and Sabouraud dextrose II agar. Microscopic examination of the strain revealed two spores in the Gram stain. The Sabouraud dextrose II agar revealed a slightly yellow, mucoid colony morphology (Fig. 1). The strain was identified as SC (95% probability) using Vitek 2 yeast 32C identification card (YST ID; bioMérieux, Durham, NC, USA). The isolate was also identified as SC (99% identical, 1322/1323) using 26s rRNA sequencing (Macrogen Inc., Seoul, Korea). On hospital day 50, the patient􏌿s central venous catheter was removed and she started fluconazole therapy for 14 days. The removed catheter tip was cultured but no microorganism was grown. On hospital day 64, fluconazole therapy was stopped. On hospital day 81, the patient had completely recovered and discharged. The same Bioflor-250 powder that was administered to the patient was incubated on Sabouraud dextrose II agar for two days at 35°C. The isolates were identified as SC by using the ID 32C-system (bioMériux, USA). The isolate was identified as SC (99% identical, 1322/1323) using 26s rRNA sequencing (Macrogen Inc., Korea) (Table 1).

Histologically thought to be nonpathogenic, SC is emerging fungal pathogen that causes thrush, vulvovaginitis, empyema and fungemia. Exposure to probiotics may contribute to the ability of the organism to colonize and infect human hosts, and important risk factors for fungemia include immunosuppression, intensive care unit stay, total parenteral nutrition, and central venous catheters [3]. SC is a teleomorph yeast showing ascospores after 2-5 days of incubation on Fowell􏌿s acetate agar or V8A (V8 Agar) medium at room temperature [3]. In routine laboratory, SC can be identified using biochemical characteristics such as those demonstrated on the carbohydrate assimilation test, and assimilation of raffinose by SC is noteworthy [3]. SC is usually susceptible to commonly used antifungal agents like liposomal amphotericin B [6]. In this case, the patient responded well to antifungal therapy.

Although probiotics with SC are usually safe, there are chance of systemic infection in premature infants with feeding intolerance, intestinal dysfunction, or immunosuppression due to cancer, HIV infection, use of corticosteroid, neutropenia, organ transplantation, burns and heart surgery [7,8].

To date, several studies have reported SC fungemia related to use of probiotics [9-11]. In premature care, probiotics can be used for prevention of necrotizing enteritis, functional gastrointestinal disorder and feeding problem. But as prior reports, in immunocompromised patients–including premature infants with central venous catheter-, there are chances for SC to cause systemic infection[4,12,13]. This case suggests that further evaluation of proper indication for probiotic administration to premature baby is needed.